Express Scripts Holding Company company logo

# RNN 1st Gen Model Express Scripts Holding Company Drug stores & proprietary stores

Prediction models:
68.18% successful of 44 deals
$ 74.72 Last close price
at 22-feb-2018

ESRX

Model's trade recommendations 5.86% Return for period

-2.82% Annual return

$43.07B Market Cap

β 0.93  

ESRX

Model (following trade recommendations)

ESRX

Underlying stock

S&P 500

Index
Return for period 5.86%
-7.52%
1.78%
52wk return -6.31%
5.34%
16.82%
52wk Range
56.81—81.92
2000.54—2399.63
Sortino ratio -0.29
Sharpe ratio -0.26
Norm. RMSE 0.58%
Downside risk 9.05%
Volatility 10.16%
  • BUY Analysts consensus recommendation

Express Scripts Holding Company puts medicine within reach of tens of millions of people by aligning with plan sponsors, taking bold action and delivering patient-centered care to make better health more affordable and accessible. Headquartered in St. Louis, Express Scripts provides integrated pharmacy benefit management services, including network-pharmacy claims processing, home delivery pharmacy care, specialty pharmacy care, specialty benefit management, benefit-design consultation, drug utilization review, formulary management, and medical and drug data analysis services. Express Scripts also distributes a full range of biopharmaceutical products and provides extensive cost-management and patient-care services.

Industry sector: Medical

Sector classification: Drug stores & proprietary stores

Deep Learning based analysis and prediction model for Express Scripts Holding Company (ESRX) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 23, 2015.

Market data for ESRX model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 563M
P/E 11.12
Shares Outstanding 566M
% Held by Insiders 0.68%
% Held by Institutions 86.45%
EPS (last reported FY) $6.39
EPS (last reported Q) $1.90
EPS, estimated (last reported Q) $1.90
Total revenues $100 B
Net income $3 B